scholarly journals Pump two-phase performance program. Volume 5. Steady-state data. Final report

1980 ◽  
Author(s):  
W. Kennedy ◽  
M. Jacob ◽  
J. Whitehouse ◽  
J. Fishburn ◽  
G. Kanupka
1980 ◽  
Author(s):  
W. Kennedy ◽  
M. Jacob ◽  
J. Whitehouse ◽  
J. Fishburn ◽  
G. Kanupka

1980 ◽  
Author(s):  
W. Kennedy ◽  
M. Jacob ◽  
J. Whitehouse ◽  
J. Fishburn ◽  
G. Kanupka

2008 ◽  
Vol 45 ◽  
pp. 161-176 ◽  
Author(s):  
Eduardo D. Sontag

This paper discusses a theoretical method for the “reverse engineering” of networks based solely on steady-state (and quasi-steady-state) data.


2011 ◽  
Vol 55 (5) ◽  
pp. 2290-2296 ◽  
Author(s):  
Thomas N. Kakuda ◽  
Samantha Abel ◽  
John Davis ◽  
Julia Hamlin ◽  
Monika Schöller-Gyüre ◽  
...  

ABSTRACTThe effects of darunavir-ritonavir at 600 and 100 mg twice daily (b.i.d.) alone, 200 mg of etravirine b.i.d. alone, or 600 and 100 mg of darunavir-ritonavir b.i.d. with 200 mg etravirine b.i.d. at steady state on the steady-state pharmacokinetics of maraviroc, and vice versa, in healthy volunteers were investigated in two phase I, randomized, two-period crossover studies. Safety and tolerability were also assessed. Coadministration of 150 mg maraviroc b.i.d. with darunavir-ritonavir increased the area under the plasma concentration-time curve from 0 to 12 h (AUC12) for maraviroc 4.05-fold relative to 150 mg of maraviroc b.i.d. alone. Coadministration of 300 mg maraviroc b.i.d. with etravirine decreased the maraviroc AUC12by 53% relative to 300 mg maraviroc b.i.d. alone. Coadministration of 150 mg maraviroc b.i.d. with etravirine-darunavir-ritonavir increased the maraviroc AUC123.10-fold relative to 150 mg maraviroc b.i.d. alone. Maraviroc did not significantly affect the pharmacokinetics of etravirine, darunavir, or ritonavir. Short-term coadministration of maraviroc with darunavir-ritonavir, etravirine, or both was generally well tolerated, with no safety issues reported in either trial. Maraviroc can be coadministered with darunavir-ritonavir, etravirine, or etravirine-darunavir-ritonavir. Maraviroc should be dosed at 600 mg b.i.d. with etravirine in the absence of a potent inhibitor of cytochrome P450 3A (CYP3A) (i.e., a boosted protease inhibitor) or at 150 mg b.i.d. when coadministered with darunavir-ritonavir with or without etravirine.


2021 ◽  
pp. 1-23
Author(s):  
Daniel O'Reilly ◽  
Manouchehr Haghighi ◽  
Mohammad Sayyafzadeh ◽  
Matthew Flett

Summary An approach to the analysis of production data from waterflooded oil fields is proposed in this paper. The method builds on the established techniques of rate-transient analysis (RTA) and extends the analysis period to include the transient- and steady-state effects caused by a water-injection well. This includes the initial rate transient during primary production, the depletion period of boundary-dominated flow (BDF), a transient period after injection starts and diffuses across the reservoir, and the steady-state production that follows. RTA will be applied to immiscible displacement using a graph that can be used to ascertain reservoir properties and evaluate performance aspects of the waterflood. The developed solutions can also be used for accurate and rapid forecasting of all production transience and boundary-dominated behavior at all stages of field life. Rigorous solutions are derived for the transient unit mobility displacement of a reservoir fluid, and for both constant-rate-injection and constant-pressure-injection after a period of reservoir depletion. A simple treatment of two-phase flow is given to extend this to the water/oil-displacement problem. The solutions are analytical and are validated using reservoir simulation and applied to field cases. Individual wells or total fields can be studied with this technique; several examples of both will be given. Practical cases are given for use of the new theory. The equations can be applied to production-data interpretation, production forecasting, injection-water allocation, and for the diagnosis of waterflood-performanceproblems. Correction Note: The y-axis of Fig. 8d was corrected to "Dimensionless Decline Rate Integral, qDdi". No other content was changed.


Author(s):  
Maral Taghva ◽  
Lars Damkilde

To protect a pressurized system from overpressure, one of the most established strategies is to install a Pressure Safety Valve (PSV). Therefore, the excess pressure of the system is relieved through a vent pipe when PSV opens. The vent pipe is also called “PSV Outlet Header”. After the process starts, a transient two-phase flow is formed inside the outlet header consisting of high speed pressurized gas interacting with existing static air. The high-speed jet compresses the static air towards the end tail of the pipe until it is discharged to the ambiance and eventually, the steady state is achieved. Here, this transient process is investigated both analytically and numerically using the method of characteristics. Riemann’s solvers and Godunov’s method are utilized to establish the solution. Propagation of shock waves and flow property alterations are clearly demonstrated throughout the simulations. The results show strong shock waves as well as high transient pressure take place inside the outlet header. This is particularly important since it indicates the significance of accounting for shock waves and transient pressure, in contrast to commonly accepted steady state calculations. More precisely, shock waves and transient pressure could lead to failure, if the pipe thickness is chosen only based on conventional steady state calculations.


2018 ◽  
Vol 14 (3) ◽  
pp. 221-238 ◽  
Author(s):  
Mariana Moreno ◽  
Jianfeng Liu ◽  
Qinglin Su ◽  
Cody Leach ◽  
Arun Giridhar ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document